A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients with Severe Haemophilia A

To evaluate immunogenicity of NNC 0129-0000-1003 (hereafter referred to as N8-GP)